Abstract
Human coronaviruses (CoV) cause respiratory infections that range from mild to severe. CoVs are a large family of viruses with considerable genetic heterogeneity and a multitude of viral types, making preventing and treating these viruses difficult. Comprehensive treatments that inhibit CoV infections fulfill a pressing medical need and may be immensely valuable in managing emerging and endemic CoV infections. As the main protease ($M^{pro}$) is highly conserved across many CoVs, this protease has been identified as a route for broad CoV inhibition. We utilize the advanced generative chemistry platform Chemistry42 for de novo molecular design and obtained novel small-molecule, non-peptide-like inhibitors targeting the SARS-CoV-2 $M^{pro}$. ISM3312 is identified as an irreversible, covalent $M^{pro}$ inhibitor from extensive virtual screening and structure-based optimization efforts. ISM3312 exhibits low off-target risk and outstanding antiviral activity against multiple human coronaviruses, including SARS-CoV-2, MERS-CoV, 229E, OC43, NL63, and HKU1 independent of P-glycoprotein (P-gp) inhibition. Furthermore, ISM3312 shows significant inhibitory effects against Nirmatrelvir-resistant $M^{pro}$ mutants, suggesting ISM3312 may contribute to reduced viral escape in these settings. Incorporating ISM3312 and Nirmatrelvir into antiviral strategy could improve preparedness and reinforce defenses against future coronavirus threats.
Introduction: The Challenge of Coronavirus Evolution
While vaccines have been a cornerstone of the COVID-19 response, the rapid evolution of coronaviruses (CoVs) and the emergence of treatment-resistant strains present a moving target. Current oral antivirals like Nirmatrelvir (the active component of Paxlovid) face two major hurdles: metabolic dependency and viral escape. Nirmatrelvir is rapidly cleared by the body and must be co-administered with Ritonavir, a "booster" that inhibits the CYP3A enzyme. This leads to a high risk of drug-drug interactions, making it unsuitable for many patients on other medications. Furthermore, mutations in the $M^{pro}$ enzyme (the drug's target) are already appearing, which reduce the efficacy of existing inhibitors. This research presents ISM3312, a "broad-spectrum" inhibitor designed to target the highly conserved $M^{pro}$ across the entire coronavirus family while working independently of boosters.
Methods: AI-Driven Molecular Discovery
The discovery of ISM3312 utilized Chemistry42, an automated generative chemistry platform integrating over 40 AI models, including Generative Adversarial Networks and Variational Autoencoders. The discovery process followed a rigorous three-round structure-based drug design (SBDD) workflow.
In Round 1, virtual screening of vendor libraries identified a primary hit based on a 4C-Ugi reaction scaffold. Round 2 focused on AI-driven hit expansion and optimization of a chloroacetamide lead. Finally, Round 3 refined the "warhead," swapping the standard chloroacetamide for an $\alpha$-chlorofluoroacetamide (CFA). This modification lowered covalent reactivity to reduce off-target risks while simultaneously improving metabolic stability in human and mouse plasma. The AI was guided by published X-ray structures of SARS-CoV-2 $M^{pro}$ (PDB: 6W63, 3V3M, and 6LU7), and its modules were trained on cysteine protease inhibitors from the ChEMBL database.
Key Insights and Results
Lead optimization revealed that the introduction of a methyl group at a specific quaternary carbon—the so-called "magic methyl"—significantly improved the molecule's binding conformation, boosting enzymatic potency to an $IC_{50}$ of 14 nM. Unlike many existing treatments, ISM3312 is not a significant substrate for the P-glycoprotein (P-gp) efflux pump, allowing it to reach therapeutic concentrations without the need for a booster drug like Ritonavir.
ISM3312 forms a permanent covalent bond with the C145 residue of the $M^{pro}$ active site. This irreversible nature provides a longer pharmacological half-life than reversible inhibitors. In cell assays, the compound maintained sub-micromolar $EC_{50}$ values across all tested variants, including MERS-CoV and common cold viruses (HCoV-229E, OC43, NL63, and HKU1). In vivo testing in mouse models infected with various SARS-CoV-2 strains (Ancestral, BA.2.3, and XBB.1) showed that oral administration of ISM3312 provided 100% protection and significantly reduced viral titers in the lungs and brain.
Conclusion and Clinical Outlook
ISM3312 represents a significant step forward in broad-spectrum antiviral development. By overcoming current resistance mechanisms (such as the E166V mutation) and eliminating the need for metabolic boosters, it offers a more flexible treatment option for diverse patient populations. While the CFA warhead reduces off-target risks, long-term safety profiles continue to be established. The compound has successfully completed a Phase I clinical trial in healthy volunteers, demonstrating its potential for rapid translation into clinical use to defend against current and future coronavirus threats.
Summary updated